SCHEMBL2366766

SCHEMBL2366766

COCC1COC(=O)N1c1ccc(C(=O)N2CCN(c3ncc(C4CC4)cc3C3CC3)CC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.37
NTSR1 P30989 1/20 0.37
MGLL Q99685 1/20 0.36
EGLN1 Q9GZT9 3/20 0.36
PIK3CA P42336 1/20 0.36
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
SSTR5 P35346 1/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 1/20 0.35
SLC6A7 Q99884 1/20 0.35
LRRK2 Q5S007 1/20 0.34
FASN P49327 2/20 0.34
KDM4E B2RXH2 2/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
POLB P06746 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2366761 1.00 LMNA (0.37) LMNANTSR1MGLLEGLN1PIK3CA
SCHEMBL2366005 0.93 EGLN1 (0.36) LMNANTSR1MGLLEGLN1KMT2A
SCHEMBL2366014 0.93 EGLN1 (0.36) LMNANTSR1MGLLEGLN1KMT2A
SCHEMBL2366668 0.93 LMNA (0.35) LMNANTSR1EGLN1KMT2AMEN1
SCHEMBL2366675 0.93 LMNA (0.35) LMNANTSR1EGLN1KMT2AMEN1
SCHEMBL2366647 0.92 LMNA (0.39) LMNANTSR1MGLLEGLN1PIK3CA
SCHEMBL2366652 0.92 LMNA (0.39) LMNANTSR1MGLLEGLN1PIK3CA
SCHEMBL2365950 0.91 P2RX3 (0.37) NTSR1EGLN1KMT2AMEN1SLC6A7
SCHEMBL2365943 0.91 P2RX3 (0.37) NTSR1EGLN1KMT2AMEN1SLC6A7
SCHEMBL2366224 0.91 ADRA1A (0.40) LMNANTSR1EGLN1PIK3CAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 LMNA 3668/4885NTSR1 3313/4885MGLL 2163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.